Clinical endpoint
|
Prognosticator
|
HR
|
95% CI
|
P value
|
---|
OS
|
CXCR4 Expression
|
2.78
|
1.78-4.35
|
<0.001
|
UICC Stage
|
1.51
|
1.15-1.98
|
0.003
|
N classification
|
1.47
|
1.16-1.88
|
0.001
|
Gender
|
0.48
|
0.29-0.80
|
0.004
|
|
Age
|
1.65
|
1.07-2.56
|
0.024
|
PFS
|
CXCR4 Expression
|
2.30
|
1.42-3.72
|
<0.001
|
ETAR Expression
|
2.12
|
1.03-4.36
|
0.04
|
|
N classification
|
1.66
|
1.31-2.08
|
<0.001
|
|
Gender
|
0.38
|
0.21-0.72
|
0.003
|
DMFS
|
CXCR4 expression
|
2.52
|
1.42-4.46
|
0.001
|
ETAR expression
|
3.46
|
1.22-9.84
|
0.02
|
|
N classification
|
1.96
|
1.48-2.59
|
<0.001
|
LRRFS
|
UICC stage
|
1.76
|
1.22-2.54
|
0.002
|
- CI confidence interval, DMFS distant metastasis-free survival, HR hazard ratio, LRRFS locoregional relapse-free survival, OS overall survival, PFS progression-free survival.